Investigational drug · Phase 3
zeleciment basivarsen
Also called: DYNE-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "zeleciment basivarsen"
First trial start
2022
Sep 5, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zeleciment basivarsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy Type 1 (DM1)
- DM1
- Myotonic Dystrophy
- Steinert Disease
- Steinert
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "zeleciment basivarsen" as an intervention, largest first.
- Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Pivotal-lookingRecruiting
Dyne TherapeuticsIndustry
NCT07486934 · 150 participants (planned) · Start May 14, 2026 · Primary completion Jul 2028
Drug: zeleciment basivarsen (DYNE-101); Placebo · For: Myotonic Dystrophy Type 1 (DM1); DM1; Myotonic Dystrophy and 2 more
Sites: La Jolla, California; Los Angeles, California; Palo Alto, California · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- From molecular convergence to clinical divergence: Comparative pathogenic mechanisms and therapeutic trajectories in C9orf72-ALS/FTD and myotonic dystrophy.
Alberti C, Parente V, Corti S, et al. · Neurobiol Dis 2025
- FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.
Weeden T, Picariello T, Quinn B, et al. · Commun Med (Lond) 2025
- The myotonic dystrophy type 1 drug development pipeline: 2022 edition.
Pascual-Gilabert M, Artero R, López-Castel A · Drug Discov Today 2023
Also in development for Myotonic Dystrophy Type 1 (DM1)
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- VX-670Phase 22 trials
Vertex Pharmaceuticals · Myotonic Dystrophy Type 1 (DM1)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.